Table 2 Patient and cancer-specific data for patients having selected major COVID-altered management decisions.

From: Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

 

Patients having omitted/incomplete NACT

Patients having ‘Bridging’ ET

Patients undergoing simple Mx when BCS possible

Patients not offered immediate breast reconstruction

Patients not having adjuvant CT

Patients not having adjuvant RT

Patients having five fractions RT

N

252c

951c

42c

299c

81c

96c

781c

Agea

52 (28–78)

65 (35–92)

59 (39–77)

50 (28–75)

63 (38–78)

69 (63–77)

59 (53–67)

Menopausal status (n)

 Pre/peri-menopausal

121 (50)

154 (18)

13 (33)

176 (61)

20 (25)

13 (15)

187 (26)

  Postmenopausal

119 (50)

708 (82)

27 (67)

113 (39)

61 (75)

76 (85)

544 (74)

  Missing

12

89

2

10

0

7

50

Tumour stage

  Is

0

87 (10)

0

23 (8)

0

16 (17)

46 (6)

  1

58 (23)

455 (50)

15 (37)

80 (27)

33 (41)

57 (61)

433 (56)

  2

142 (57)

310 (34)

23 (56)

132 (44)

39 (49)

15 (16)

252 (33)

  3

40 (16)

50 (6)

2 (5)

58 (20)

6 (8)

4 (4)

40 (5)

  4

10 (4)

4 (0)

1 (2)

4 (1)

2 (2)

2 (2)

3 (0)

  Missing

2

45

1

2

1

2

7

Nodal stage

  0/mi

125 (50)

760 (84)

23 (56)

175 (59)

36 (45)

82 (86)

638 (83)

  1

75 (30)

124 (14)

14 (34)

76 (26)

41 (51)

12 (13)

112 (15)

  2

33 (13)

10 (1)

4 (10)

32 (11)

3 (4)

1 (1)

15 (2)

  3

17 (7)

6 (1)

0 (0)

14 (5)

0 (0)

0 (0)

6 (1)

  Missing

2

51

1

2

1

1

10

Metastases

  M0

248 (99)

897 (100)

41 (100)

293 (99)

80 (100)

95 (100)

770 (100)

  M1

2 (1)

3 (0)

0 (0)

3 (1)

0 (0)

0 (0)

3 (0)

  Missing

2

51

1

3

1

1

8

  Size

MMG/USS

MMG/USS

MMG/USS

MMG/USS

Path.

Path.

Path.

  Size in mmb

29·0 (1.2)

20·7 (0.5)

24·2 (2.2)

32·8 (1.5)

27·5 (1.8)

17·8 (1.4)

20·3 (0.6)

 

28·3 (1.0)

16·9 (0.4)

23·7 (1.9)

23·9 (1.0)

   

  Missing

9/8

34/39

1/1

13/9

1

3

20

Histological type

  IDC

226 (92)

599 (65)

39 (95)

207 (71)

65 (82)

65 (71)

548 (72)

  ILC

7 (3)

149 (16)

0 (0)

48 (16)

8 (10)

5 (5)

107 (14)

  Mixed

4 (2)

31 (3)

1 (2)

9 (3)

3 (4)

1 (1)

26 (3)

  Other

9 (4)

54 (6)

1 (2)

6 (2)

3 (4)

5 (5)

40 (5)

  DCIS

0

94 (10)

0

232 (8)

0

16 (17)

45 (6)

  Missing

6

24

1

6

2

1

15

Grade (invasive)

  1

2 (1)

204 (25)

1 (2)

14 (5)

3 (4)

19 (26)

126 (18)

  2

67 (27)

507 (62)

14 (34)

147 (54)

42 (53)

43 (58)

407 (57)

  3

178 (72)

109 (13)

26 (63)

110 (41)

35 (44)

12 (16)

181 (25)

  Missing

5

37

1

5

1

3

67

Grade (DCIS)

  LG

0

12 (14)

0

1 (4)

0

0 (0)

0 (0.0)

  IG

0

29 (33)

0

5 (23)

0

4 (27)

12 (27)

  HG

0

46 (53)

0

16 (73)

0

11 (73)

33 (73)

  Missing

0

7

0

1

0

1

0

ER

  +

121 (49)

922 (100)

24 (59)

221 (76)

59 (73)

76 (89)

656 (86)

  −

127 (51)

3 (0)

17 (41)

71 (24)

22 (27)

9 (11)

104 (14)

  Missing

4

26

1

7

0

8

21

PR

  +

78 (33)

620 (85)

19 (48)

160 (63)

48 (66)

51 (72)

462 (71)

  −

155 (67)

106 (15)

21 (52)

95 (37)

25 (34)

20 (28)

188 (29)

  Missing

19

225

2

44

8

21

221

HER2

  +

116 (47)

63 (8)

8 (20)

71 (26)

21 (26)

3 (4)

85 (12)

  −

132 (53)

761 (92)

33 (80)

205 (74)

59 (74)

75 (96)

636 (88)

  Missing

4

137

1

23

1

15

60

  Ki67b

36·2 (3·6)

18·8 (2·5)

29·6 (5·1)

27·4 (3·4)

24·4 (6·0)

14.6 (2·5)

19.8 (1·6)

  Missing

213

847

24

246

65

75

654

Comorbidities

  None

6 (2)

46 (5)

1 (2)

6 (2)

1 (1)

4 (4)

19 (2)

  ≥1

246 (98)

905 (95)

41 (98)

293 (98)

80 (99)

92 (96)

762 (98)

  Missing

0

0

0

0

0

0

0

WHO PS

  0

197 (79)

667 (71)

28 (67)

261 (87)

63 (78)

61 (64)

658 (85)

  1

40 (16)

180 (19)

9 (21)

29 (10)

14 (17)

26 (27)

104 (13)

  2

11 (4)

74 (8)

5 (12)

9 (3)

4 (5)

7 (7)

13 (2)

  3

2 (1)

13 (1)

0 (0)

0 (0)

0 (0)

2 (2)

2 (0)

  4

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

  Missing

2

17

0

0

0

0

4

  1. NACT   neoadjuvant chemotherapy, ET neoadjuvant endocrine therapy, Mx mastectomy, BCS   breast-conserving surgery, CT   chemotherapy, RT   radiotherapy, IDC   invasive ductal carcinoma, ILC   invasive lobular carcinoma, DCIS   ductal carcinoma in situ, LG   low grade, IG   intermediate grade, HG   high grade, ER   oestrogen receptor, PR   progesterone receptor, HER2   Human epidermal growth factor receptor 2, PS   performance status.
  2. aMedian (IQR).
  3. bMean (SD).
  4. cPatients could be in more than one category.
Back to article page